Genfit May Be Gaining An Edge In NASH Race
With Intercept encountering safety concerns for Ocaliva and mixed data for Gilead's and Allergan's NASH candidates, Genfit may hold an advantage with NASH clearance ability and clean safety profile.
You may also be interested in...
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.
A week after Gilead missed its primary endpoint in the first Phase III NASH trial, Intercept shows a statistically significant fibrosis benefit in Phase III with OCA. It plans to file for approval later this year.
Primary endpoint miss for Phase III selonsertib in cirrhotic NASH patients follows disappointing data at both 2018 major liver conferences. STELLAR-3 in NASH patients with bridging fibrosis looms large for Gilead’s hopes.